XERS vs. ENTA, MGNX, CTNM, INZY, NLTX, AQST, RANI, XBIT, CRMD, and VTYX
Should you be buying Xeris Biopharma stock or one of its competitors? The main competitors of Xeris Biopharma include Enanta Pharmaceuticals (ENTA), MacroGenics (MGNX), Contineum Therapeutics (CTNM), Inozyme Pharma (INZY), Neoleukin Therapeutics (NLTX), Aquestive Therapeutics (AQST), Rani Therapeutics (RANI), XBiotech (XBIT), CorMedix (CRMD), and Ventyx Biosciences (VTYX). These companies are all part of the "pharmaceutical preparations" industry.
Xeris Biopharma (NASDAQ:XERS) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, community ranking, media sentiment, valuation, profitability and risk.
Xeris Biopharma has a net margin of -37.58% compared to Enanta Pharmaceuticals' net margin of -180.76%. Enanta Pharmaceuticals' return on equity of -64.85% beat Xeris Biopharma's return on equity.
Xeris Biopharma currently has a consensus price target of $4.63, suggesting a potential upside of 128.96%. Enanta Pharmaceuticals has a consensus price target of $19.00, suggesting a potential upside of 58.33%. Given Xeris Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Xeris Biopharma is more favorable than Enanta Pharmaceuticals.
Xeris Biopharma has a beta of 2.37, suggesting that its share price is 137% more volatile than the S&P 500. Comparatively, Enanta Pharmaceuticals has a beta of 0.54, suggesting that its share price is 46% less volatile than the S&P 500.
Enanta Pharmaceuticals received 170 more outperform votes than Xeris Biopharma when rated by MarketBeat users. However, 69.65% of users gave Xeris Biopharma an outperform vote while only 56.47% of users gave Enanta Pharmaceuticals an outperform vote.
In the previous week, Enanta Pharmaceuticals had 1 more articles in the media than Xeris Biopharma. MarketBeat recorded 1 mentions for Enanta Pharmaceuticals and 0 mentions for Xeris Biopharma. Enanta Pharmaceuticals' average media sentiment score of 0.01 beat Xeris Biopharma's score of 0.00 indicating that Enanta Pharmaceuticals is being referred to more favorably in the news media.
42.8% of Xeris Biopharma shares are owned by institutional investors. Comparatively, 95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. 4.6% of Xeris Biopharma shares are owned by company insiders. Comparatively, 13.6% of Enanta Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Xeris Biopharma has higher revenue and earnings than Enanta Pharmaceuticals. Xeris Biopharma is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Xeris Biopharma beats Enanta Pharmaceuticals on 10 of the 18 factors compared between the two stocks.
Get Xeris Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for XERS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding XERS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Xeris Biopharma Competitors List
Related Companies and Tools
